COMPANY
Relation Therapeutics
Relation Therapeutics uses a Lab-in-the-Loop approach to drug target discovery and development. From company website Source · checked 2026-10-19
Sources for this description (1)
- Relation Therapeutics uses a Lab-in-the-Loop approach to drug target discovery and development.
- “At Relation, we pioneer a Lab-in-the-Loop approach to drug target discovery and development.” https://www.relationrx.com/science (2026-10-19)
Sourced facts
- ClinicalTrials.gov studies as lead sponsor: 2 (query "Relation Therapeutics") · clinicaltrials.gov · checked Oct 15, 2026
- SEC Form D filings: 4 (query "Relation Therapeutics") · efts.sec.gov · checked Oct 15, 2026
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Research Assistant – Cell Biology (Contractor) | London, United Kingdom | Oct 13, 2026 | Oct 14, 2026 |
| Machine Learning Scientist, Generative Modelling | London, United Kingdom | Oct 6, 2026 | Oct 14, 2026 |
| Manager/Associate Director - Project Management | London, United Kingdom | Sep 25, 2026 | Oct 14, 2026 |
| Director, Clinical Pharmacology | London, United Kingdom | Aug 25, 2026 | Oct 14, 2026 |
| Associate Director, Platform Engineering | London, United Kingdom | Aug 21, 2026 | Oct 14, 2026 |
Open jobs 13
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Research Assistant – Cell Biology (Contractor) | London, United Kingdom | Oct 13, 2026 | Oct 14, 2026 | Entry |
| Machine Learning Scientist, Generative Modelling | London, United Kingdom | Oct 6, 2026 | Oct 14, 2026 | Mid |
| Manager/Associate Director - Project Management | London, United Kingdom | Sep 25, 2026 | Oct 14, 2026 | Senior |
| Director, Clinical Pharmacology | London, United Kingdom | Aug 25, 2026 | Oct 14, 2026 | Senior |
| Associate Director, Platform Engineering | London, United Kingdom | Aug 21, 2026 | Oct 14, 2026 | Senior |
| Machine Learning Scientist – Sequence Modelling | London, United Kingdom | Aug 20, 2026 | Oct 14, 2026 | Mid |
| Senior Data Scientist (Single Cell) | London, United Kingdom | Aug 11, 2026 | Oct 14, 2026 | Senior |
| Machine Learning Research Engineer | London, United Kingdom | Aug 11, 2026 | Oct 14, 2026 | Senior |
| Senior Machine Learning Scientist (Generative Modelling) | London, United Kingdom | Aug 11, 2026 | Oct 14, 2026 | Senior |
| Senior Data Scientist (Imaging) | London, United Kingdom | Aug 11, 2026 | Oct 14, 2026 | Senior |
| Snr Data Scientist, Computational Genomics/DNA Modelling | London, United Kingdom | Jul 3, 2026 | Oct 14, 2026 | Mid |
| Platform Engineer | London, United Kingdom | Jan 7, 2026 | Oct 14, 2026 | Mid |
| Talent Pool | London, United Kingdom | Dec 12, 2024 | Oct 14, 2026 | Not stated |
Funding and NIH signals
- SEC Form D raise Raised $36.18M in debt securities (Form D filed Dec 9, 2025); since then posted 14 roles. SEC Form D 0001876828-25-000003 (Dec 9, 2025)
Evidence (1 event)
- Dec 9, 2025 · SEC Form D 0001876828-25-000003
Name of Issuer: Relation Therapeutics Inc.; CIK: 1876828; Address: Miami Beach, FL; Submission type: D; Filing date: 2025-12-09; Industry Group: Biotechnology; Date of First Sale: 2025-11-21; Types of Securities Offered: Debt, Security to be acquired, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 36175000; Total Amount Sold: 36175000; Federal exemptions: 06b
- Dec 9, 2025 · SEC Form D 0001876828-25-000003
Connect
See your connections at Relation Therapeutics on LinkedIn (search by name, results not checked)
Raises and deals from press releases
- Deal GSK deal · amount not disclosed · announced Jul 30, 2026 Company release ↗
Source quote
- Jul 30, 2026 · Company release ↗
“Relation Announces Expanded Collaboration with GSK”
- Jul 30, 2026 · Company release ↗